This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ASM journals Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pajukanta, R Articles by Jousimies-Somer, H Search for Related Content PubMed PubMed Citation Articles by Pajukanta, R Articles by Jousimies-Somer, H

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1992 June; 36(6): 1241-1243

In vitro activity of azithromycin compared with that of erythromycin against Actinobacillus actinomycetemcomitans.

R Pajukanta, S Asikainen, M Saarela, S Alaluusua and H Jousimies-Somer

Department of Periodontology, University of Helsinki, Finland.

ABSTRACT

The in vitro susceptibility of Actinobacillus actinomycetemcomitans to azithromycin, a new macrolide antibiotic of a new class known as azalides, was compared with that of erythromycin by the agar dilution method on Mueller-Hinton Haemophilus test medium. Eighty-two A. actinomycetemcomitans strains, 79 recent clinical isolates obtained from 40 periodontally healthy or diseased subjects, and 3 type strains were included in the study. Erythromycin showed poor in vitro activity against A. actinomycetemcomitans. Azithromycin, however, was highly effective against A. actinomycetemcomitans: all strains were inhibited at 2.0 micrograms/ml. Azithromycin exhibited the best in vitro activity against the serotype a subpopulation of A. actinomycetemcomitans: 100% of the strains were inhibited at 1.0 micrograms/ml. The lowest MICs were, however, recorded by serotype b strains. Since azithromycin has favorable pharmacokinetic properties, including excellent distribution into tissues, it could be expected to pass into gingival crevicular fluid at levels sufficient to inhibit A. actinomycetemcomitans in vivo. Therefore, it is a good candidate for future clinical trials in A. actinomycetemcomitans-associated periodontitis.

---

Antimicrob Agents Chemother. 1992 June; 36(6): 1241-1243

This article has been cited by other articles:

• Chou, C.-H., Walters, J.D. (2008). Clarithromycin Transport by Gingival Fibroblasts and Epithelial Cells. JDR 87: 777-781 [Abstract] [Full Text]  
• Piccolomini, R., Catamo, G., Di Bonaventura, G. (1998). Bacteriostatic and Bactericidal In Vitro Activities of Clarithromycin and Erythromycin against Periodontopathic Actinobacillus actinomycetemcomitans. Antimicrob. Agents Chemother. 42: 3000-3001 [Abstract] [Full Text]